In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

AstraZeneca Q3 Preview: Oncology Portfolio Keeps Growing

AstraZeneca, which analysts said had an 'exceptional' second quarter, is expected to have also kept that momentum up in the third quarter.
Sales & Earnings Companies

Roche Ups Outlook, Sees Spark Buy By Year-End

Roche presented another strong quarterly performance and raised its outlook again for the full year, as sales continued to be driven in the third quarter by its portfolio of new medicines. It still believes its delayed takeover of Spark Therapeutics will happen by year-end.  

 

Sales & Earnings Commercial

Novo Nordisk, Bluebird Targeting ‘Lifelong’ Gene Therapies

Novo Nordisk and bluebird bio will jointly develop genome editing treatments for genetic diseases, beginning with hemophilia.
Commercial Companies

Lord O’Neill Blames Governments And Pharma For Faltering AMR Progress

Three years after completion of his high-profile AMR Review, Jim O’Neill warns that global progress on antimicrobial resistance has slowed dangerously.

Commercial Policy & Regulation

Label Battles: Beovu And Eylea Contest Begins In AMD

Shares in Eylea-maker Regeneron slid after FDA approved Novartis's competing VEGF inhibitor for treating AMD, but some observers said investors had overreacted.

Commercial Companies

Ex Shire CEO Ornskov Resurfaces To Lead Skin Group Galderma

A group of investors has bought Nestlé Skin Health, renamed it Galderma to capitalize on its legacy in dermatology and put M&A veteran, former Shire CEO Flemming Ornskov, at its helm.

Leadership Companies
See All
Advertisement
UsernamePublicRestriction

Register